Incyte Corp Call to Discuss Pemigatinib Development Update from European Society for Medical Oncology
Conference Call Incyte Corp
Incyte Corp Conference call or earnings call will be held on Sep 27, 2019 via an 800 number (toll-free). During the earnings conference call's session Incyte Corp will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Incyte Corp for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we believe have the greatest likelihood of creating near-and long-term value and on compounds that we believe a company of our size can effectively develop and commercialize on its own, or that we can further develop and commercialize through strategic relationships. Our highest priority programs involve our janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications and oral INCB28050 for chronic inflammatory and autoimmune diseases.Read more Conference Call